Phosphodiesterases (PDEs) play a central role in the regulation of various signaling cascades by specifically hydrolyzing the cyclic nucleotides, cAMP, and cGMP into their nucleoside 5’ -– monophosphate form AMP and GMP respectively. Hydrolysis of these nucleotides results in the breakdown of these secondary messengers and the abrogation of downstream signaling. Given the importance of these enzymes in the regulation of cAMP/cGMP signaling, PDEs have been identified as an important class of potential drug targets in diseases such as cancer, neurodegeneration, coronary heart diseases, asthma and more.

Signalchem has successfully manufactured 19 of the 24 phosphodiesterases from the human genome as active enzymes. Our recombinant PDEs are compatible with their substrates cAMP and cGMP and are ready to be included in enzyme activity and inhibitor profiling assays. Our PDEs are tested exclusively using Promega's PDE-Glo™ Assay technology.